Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORMD-0801 in Type 1 Diabetes
NCT00867594Phase 2Completed
- Sponsor
- Hadassah Medical Organization
- Start
- Jul 2008
- Primary completion
- Aug 2008
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ORMD-0801 in type 1 diabetes mellitus (T1D), sponsored by Hadassah Medical Organization. Primary endpoint: Safety and tolerability of multi-doses of Oramed oral insulin at 15 days. Started Jul 2008; status: completed.
02
Drugs
ORMD-0801
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00867594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00867594.